Aceto Corporation (ACET): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACET Stock Price Chart Interactive Chart >
ACET Price/Volume Stats
| Current price | $11.77 | 52-week high | $21.70 |
| Prev. close | $11.75 | 52-week low | $9.71 |
| Day low | $11.62 | Volume | 84,700 |
| Day high | $11.96 | Avg. volume | 128,032 |
| 50-day MA | $13.36 | Dividend yield | N/A |
| 200-day MA | $13.57 | Market Cap | 374.45M |
Aceto Corporation (ACET) Company Bio
Aceto Corporation sources, markets, sells, and distributes pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products, and specialty chemicals. The company was founded in 1947 and is based in Port Washington, New York.
Latest ACET News From Around the Web
Below are the latest news stories about Adicet Bio Inc that investors may wish to consider to help them evaluate ACET as an investment opportunity.
Adicet Bio Announces Initiation of its First-in-Human Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's LymphomaAdicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that it has initiated its First-in-Human Phase I clinical trial evaluating ADI-001 for the treatment of B cell non-Hodgkin's lymphoma (NHL). ADI-001 is an investigational first-in-class allogeneic gamma delta T cell therapy expressing a chimeric antigen receptor (CAR) targeting CD20, engineered to potentially enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. |
Adicet Bio Appoints Dr. Andrew Sinclair to its Board of DirectorsMENLO PARK, Calif. and BOSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Andrew Sinclair, Ph.D., to its board of directors. Dr. Sinclair will replace Erez Chimovits, who will step down from the Board of Directors. “Abingworth was a significant investor in our recent successful $152 million financing and we are extremely pleased to welcome Andrew, a highly-respected healthcare investor, to our Board of Directors,” said Chen Schor, President and Chief Executive Officer of Adicet Bio, Inc. “Andrew’s significant life science experience amassed throughout his career, both from the financial and scientific perspe... |
We're Hopeful That Adicet Bio (NASDAQ:ACET) Will Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
Adicet Reports Third Quarter 2020 Financial Results and Provides Business UpdateMENLO PARK, Calif. and BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today reported financial results for the third quarter ended September 30, 2020. “We are extremely proud of the milestones we’ve achieved this quarter, including the completion of the merger between Adicet Bio and resTORbio, the clearance of our IND application for ADI-001, and the expansion of our executive team with the appointment of Nick Harvey as CFO and, more recently, Don Healey, Ph.D., as CTO,” said Chen Schor, President and Chief Executive Officer of Adicet. “Looking ahead, we expect to initiate the Phase 1 clinical trial for ADI-001 in the first... |
Adicet Appoints Don Healey, Ph.D., as Chief Technology OfficerMENLO PARK, Calif. and BOSTON, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Don Healey, Ph.D., as Chief Technology Officer. Dr. Healey will lead the development of Adicet’s genetically-modified T cell therapies for clinical development and commercialization, including manufacturing, viral vector operations and analytics. “We are excited to welcome Don as a new member of Adicet’s Executive Leadership Team,” said Chen Schor, President and Chief Executive Officer of Adicet. “Don’s expertise in guiding the production and release of cell therapy products, as well as his deep knowledge of the scientif... |
ACET Price Returns
| 1-mo | -12.30% |
| 3-mo | -22.51% |
| 6-mo | -20.31% |
| 1-year | -22.87% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -16.23% |
| 2020 | 34.71% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...